IIT-B startup ImmunoACT’s “affordable” blood cancer therapy gets regulatory approval – a first for India’s CAR-T cell therapy

The Indian drug regulator has granted approval to ImmunoACT for its CAR-T cell therapy NexCAR19, designed to treat certain types of blood cancers. The therapy will be used for the treatment of relapsed/refractory B-cell lymphomas and leukemia in India.

Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News